The Expression of PD-L1, BRAF<sup>V600E</sup>, CD68 Protein and the Significance of Tumor Infiltrating Lymphocytes in the Diagnosis of Malignant Melanoma

Xilan WU; Hong SHEN; Susheng SHI; Zhihui ZHANG; Lei GUO; Fang WANG

doi:10.12259/j.issn.2095-610X.S20220923

Volume 43 Issue 9

Sep. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(9): 13-18

Xilan WU, Hong SHEN, Susheng SHI, Zhihui ZHANG, Lei GUO, Fang WANG. The Expression of PD-L1, BRAFV600E, CD68 Protein and the Significance of Tumor Infiltrating Lymphocytes in the Diagnosis of Malignant Melanoma[J]. Journal of Kunming Medical University, 2022, 43(9): 13-18. doi: 10.12259/j.issn.2095-610X.S20220923

Citation:

Xilan WU, Hong SHEN, Susheng SHI, Zhihui ZHANG, Lei GUO, Fang WANG. The Expression of PD-L1, BRAF^V600E, CD68 Protein and the Significance of Tumor Infiltrating Lymphocytes in the Diagnosis of Malignant Melanoma[J]. Journal of Kunming Medical University, 2022, 43(9): 13-18. doi: 10.12259/j.issn.2095-610X.S20220923

Citation:

PDF( 1001 KB)

The Expression of PD-L1, BRAF^V600E, CD68 Protein and the Significance of Tumor Infiltrating Lymphocytes in the Diagnosis of Malignant Melanoma

doi: 10.12259/j.issn.2095-610X.S20220923

Xilan WU^{1, 2},
Hong SHEN³,
Susheng SHI⁴,
Zhihui ZHANG⁴,
Lei GUO⁴,
Fang WANG^{1
,
,}

1.
Dept. of Pathology and Pathophysiology，School of Basic Medicine，Kunming Medical University，Kunming Yunnan 650500
2.
Dept. of Pathology，Chui Yang Liu Hospital Affiliated to Tsinghua University，Beijing 100022
3.
Dept. of Pathology，The 1st People’s Hospital of Zhaotong，Zhaotong Yunnan 657000
4.
Dept. of Pathology，Cancer Hospital of Peking Union Medical College，Chinese Academy of Medical Sciences，Beijing 100021，China

Received Date: 2022-06-27
Available Online: 2022-09-07
Publish Date: 2022-09-29

Abstract

Abstract

Objective To analyze the significance of PD-L1, BRAF^V600E, CD68 protein expressions and tumor infiltrating lymphocytes （TIL） in the diagnosis of malignant melanoma. Methods High-throughput tissue microarray technology and immunohistochemical methods were used to detect the expressions of PD-L1, BRAFV600E and CD68 in 60 primary malignant melanoma tissues. The relationship between PD-L1, BRAF^V600E, CD68 expressions, TIL and the clinicopathological characteristics and prognosis of patients was analyzed. Results （1） There was a statistically significant difference between CD68 expression in malignant melanoma tissue and tumor T stage （P = 0.018）, but no statistical difference between tumor size, tumor invasion depth, lymph node metastasis and ulceration （P > 0.05）. （2） There was no significant difference between PD-L1, BRAF^V600E, TIL and tumor T stage, tumor size, tumor invasion depth, lymph node metastasis and ulceration （P > 0.05）. （3） The mutation rate of BRAF^V600E in cutaneous melanoma was about 36.67% （22/60）. The mutation rate of BRAF^V600E in cutaneous acral melanoma was about 68.18%. （15/22）. The mutation rate of BRAF^V600E in mucosal melanoma was about 23.33% （14/60）. （4） Cox regression analysis showed that lymph node metastasis was the prognostic factor of malignant melanoma patients. Conclusion （1） The expression of CD68 protein may play a role in determining the prognosis of patients. （2） BRAF^V600E immunohistochemical detection is recommended for melanoma in the skin. （3） The presence of lymph node metastasis in patients can be used as a reference index for the prognosis of malignant melanoma.
- Malignant Melanoma,
- PD-L1,
- BRAF^V600E,
- CD68,
- TIL,
- Immunohistochemistry

FullText(HTML)

References(23)

References

[1]	Christopher P Wild, Elisabete Weiderpass, Bernard W Stewart. World cancer report-cancer research for cancer prevention[M]. Lyon: World Health Organization, 2020: 374-381.
[2]	Edge S B, Byrd D R, Compton C C, et al. AJCC cancer staging manual （7th ed） [M]. New York: Springer International Publishing, 2010: 325-344.
[3]	Liu X,Zheng S P,Peng Y,et al. Construction of the prediction model for locally advanced rectal cancer following neoadjuvant chemoradiotherapy based on pretreatment tumor-infiltrating macrophage-associated biomarkers[J]. OncoTargets and Therapy,2021,14:2599-2610.
[4]	刘伟,安杰,侯会池,等. H l F-1 0c及CD68在胃癌组织中的表达及其临床意义[J]. 中国现代普通外科进展,2014,17(7):516-519.
[5]	Atefi M,Avramis E,Lassen A,et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma[J]. Clinical Cancer Research,2014,20(13):3446-3457. doi: 10.1158/1078-0432.CCR-13-2797
[6]	Kim J W, Eder J P. Prospects for targeting PD-1 and PD-L1 in various tumor types [J]. Oncology, 2014, 28 （Suppl 3）: 15-28.
[7]	Park S J,Namkoong H,Doh J,et al. Negative role of inducible PD-1 on survival of activated dendritic cells[J]. J Leukoc Biol,2014,95(4):621-629. doi: 10.1189/jlb.0813443
[8]	Merelli B,Massi D,Cattaneo L,et al. Targeting the PD1/PD-L1 axis in melanoma:Biological rationale,clinical challenges and opportunities[J]. Critical Reviews in Oncology/Hematology,2014,89(1):140-165. doi: 10.1016/j.critrevonc.2013.08.002
[9]	林喜娜,李广秋,何萍,等. 非小细胞肺癌中PD-L1表达及其与肺癌相关驱动基因的关系[J]. 临床与实验病理学杂志,2019,35(7):767-771. doi: 10.13315/j.cnki.cjcep.2019.07.003
[10]	黄育刚,王莉,汤显斌. PD-1/PD-L1免疫抑制剂在肺癌临床治疗和病理检测中的研究进展[J]. 临床与实验病理学杂志,2020,36(6):688-692.
[11]	Massi D,Brusa D,Merelli B,et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics[J]. Annals of Oncology,2014,25(12):2433-2442. doi: 10.1093/annonc/mdu452
[12]	Gadiot J,Hooijkaas A I,Kaiser A D M,et al. Overall survival and PD-L1 expression in metastasized malignant melanoma[J]. Cancer,2011,117(10):2192-2201. doi: 10.1002/cncr.25747
[13]	de Souza Malaspina T S,Gasparoto T H,Costa M R S N,et al. Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma[J]. Cancer Immunology,Immunotherapy,2011,60(7):965-974.
[14]	Muenst S,Schaerli A R,Gao F,et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer[J]. Breast Cancer Research and Treatment,2014,146(1):15-24. doi: 10.1007/s10549-014-2988-5
[15]	冯昌银,郑巧灵,黄建平. 等结直肠癌肿瘤原发灶与肝脏转移灶中PD-L1表达的差异性[J]. 临床与实验病理学杂志,2018,34(12):1340-1343.
[16]	Pinto C A,Liu Xinyue,Li Xiaoyun,et al. Treatment and overall survival among anti-PD-1-exposed advanced melanoma patients with evidence of disease progression[J]. Immunotherapy,2022,14(4):201-214.
[17]	Flaherty K T,Puzanov I,Kim K B,et al. Inhibition of mutated,activated BRAF in metastatic melanoma[J]. New England Journal of Medicine,2010,363(9):809-819. doi: 10.1056/NEJMoa1002011
[18]	黄志敏,吴一龙. 非小细胞肺癌的BRAF基因突变及其临床意义[J]. 中国肺癌杂志,2012,15(3):183-186. doi: 10.3779/j.issn.1009-3419.2012.03.09
[19]	Feller J K,Yang S,Mahalingam M. Immunohistochemistry with a mutation- specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma[J]. Mod Pathol,2013,26(3):414-420. doi: 10.1038/modpathol.2012.168
[20]	Halapi E. Oligoclonal T cells in human cancer[J]. Med Oncol,1998,15(4):203-211. doi: 10.1007/BF02787202
[21]	Rosenberg S A,Restifo N P,Yang J C,et al. Adoptive cell transfer:A clinical path to effective cancer immunotherapy[J]. Nature Reviews Cancer,2008,8(4):299-308. doi: 10.1038/nrc2355
[22]	Wang R,Zhang J,Chen S,et al. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression[J]. Lung Cancer,2011,74(2):188-196. doi: 10.1016/j.lungcan.2011.04.009
[23]	Leek R D,Lewis C E,Whitehouse R,et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma[J]. Cancer Res,1996,56(20):4625-4629.

Relative Articles(20)

Relative Articles

[1]	Wangxun SHEN, Yinyu YANG, Canwei LI, Jinrong YANG, Sijing WU, Huajun ZHAO, Xiaoyu TUO. Expression and Clinical Significance of ROR1 in Different Histologic Types of Invasive Lung Adenocarcinoma. Journal of Kunming Medical University, 2024, 45(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20240509
[2]	Cuihua FANG, Maohua PAN, Longcan ZHOU, Yucheng QIN, Yaming HUANG, Jia MA, Xi CHEN, Zhaoqing YANG. Current Status and Research Progress of Immunotherapy for Melanoma. Journal of Kunming Medical University, 2023, 44(5): 175-179. doi: 10.12259/j.issn.2095-610X.S20230519
[3]	Haixia ZHANG, Lei LI, Lei JIN, Peijing YE, Chuanzheng SUN. Clinical Features of 1,203 Melanoma Cases in Yunnan Cancer Hospital. Journal of Kunming Medical University, 2022, 43(8): 56-60. doi: 10.12259/j.issn.2095-610X.S20220808
[4]	Huajun ZHAO, Guoqing PAN, Ying TANG, Zhiyuan WANG, Xiaowei ZHAO, Xiaoyu TUO. Expressions of ROR1 in Lung Adenocarcinoma and Its Relationship with Spread Through Air Apace. Journal of Kunming Medical University, 2022, 43(11): 22-29. doi: 10.12259/j.issn.2095-610X.S20221128
[5]	Ran Zhen , Zhu Yun Sha , Hai Bing , Zhang Jing Song . Relationship between the Proportion of Tumor Infiltrating Lymphocytes in Tumor Mass and Postoperative Recurrence of Prostate Carcinoma. Journal of Kunming Medical University, 2018, 39(03): 62-66.
[6]	Liu Jun . . Journal of Kunming Medical University,
[7]	Yang Han . . Journal of Kunming Medical University,
[8]	Xu Jian Xin . . Journal of Kunming Medical University,
[9]	Zhao Yun Hong . . Journal of Kunming Medical University,
[10]	Zhang Zhen Guang . . Journal of Kunming Medical University,
[11]	Zhou Shu . . Journal of Kunming Medical University,
[12]	He Hai Yu . . Journal of Kunming Medical University,
[13]	Yu Jie . . Journal of Kunming Medical University,
[14]	Chen Yong Sheng . . Journal of Kunming Medical University,
[15]	. Culture and Identification of Hippocampus Neurons in Adult Rats. Journal of Kunming Medical University,
[16]	. Effects of Cyclosporine A on RAF-1 Expression in Skeletal Muscles of Hindlimbs in Adult Rats after Spinal Cord Transaction. Journal of Kunming Medical University,
[17]	. . Journal of Kunming Medical University,
[18]	Li Xiao Ming . . Journal of Kunming Medical University,
[19]	Su Xing . . Journal of Kunming Medical University,
[20]	Wang Xiao Li . . Journal of Kunming Medical University,